
Keywords: 5α-R; 5α-reductase type 2; ADME; absorption, distribution, metabolism and excretion; AG; andrographolide; AGD; anogenital distance; AOP; adverse outcome pathway; AR; androgen receptor; BPAD; biological pathway altering dose; CHH; congenital hypogonadotr